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Abstract
Aims/hypothesis Insulin resistance (IR) links obesity to type 2
diabetes. The aim of this study was to explore whether white
adipose tissue (WAT) epigenetic dysregulation is associated
with systemic IR by genome-wide CG dinucleotide (CpG)
methylation and gene expression profiling in WAT from
insulin-resistant and insulin-sensitive women. A secondary
aim was to determine whether the DNAmethylation signature
in peripheral blood mononuclear cells (PBMCs) reflects WAT
methylation and, if so, can be used as a marker for systemic
IR.
Methods From 220 obese women, we selected a total of 80
individuals from either of the extreme ends of the distribution
curve of HOMA-IR, an indirect measure of systemic insulin
sensitivity. Genome-wide transcriptome and DNA CpGmeth-
ylation profiling by array was performed on subcutaneous
(SAT) and visceral (omental) adipose tissue (VAT). CpG
methylation in PBMCs was assayed in the same cohort.
Results There were 647 differentially expressed genes (false
discovery rate [FDR] 10%) in SAT, all of which displayed
directionally consistent associations in VAT. This suggests that
IR is associatedwith dysregulated expression of a common set of
genes in SATandVAT. The average degree of DNAmethylation
did not differ between the insulin-resistant and insulin-sensitive
group in any of the analysed tissues/cells. There were 223 IR-
associated genes in SAT containing a total of 336 nominally
significant differentially methylated sites (DMS). The 223 IR-
associated genes were over-represented in pathways related to
integrin cell surface interactions and insulin signalling and in-
cluded COL5A1, GAB1, IRS2, PFKFB3 and PTPRJ. In VAT
there were a total of 51 differentially expressed genes (FDR
10%); 18 IR-associated genes contained a total of 29 DMS.
Conclusions/interpretation In individuals discordant for insu-
lin sensitivity, the average DNA CpG methylation in SAT and
VAT is similar, although specific genes, particularly in SAT,
display significantly altered expression and DMS in IR, pos-
sibly indicating that epigenetic regulation of these genes in-
fluences metabolism.




DMS Differentially methylated sites
FDR False discovery rate
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PBMC Peripheral blood mononuclear cell
qPCR Quantitative real-time PCR
SAT Subcutaneous adipose tissue
TRAIL TNF-related apoptosis-inducing ligand
UTR Untranslated region
VAT Visceral adipose tissue
VEGFR Vascular endothelial growth factor receptor
WAT White adipose tissue
Introduction
The impaired ability of insulin to induce cellular responses
(i.e. insulin resistance [IR]) is a pathophysiological mecha-
nism that links obesity to metabolic disorders such as type 2
diabetes and cardiovascular disease [1]. Both genetic and epi-
genetic factors are implicated in the development of systemic
IR [2], which may be characterised by elevated circulating
levels of insulin in the fasting state despite normal or elevated
glucose levels. The association between IR and excess ab-
dominal fat, in particular in the intra-abdominal or visceral
adipose tissue (VAT) depot, is believed to be mediated by
increased spontaneous hydrolysis of lipids (i.e. adipocyte li-
polysis) [3]. Released NEFA can induce IR in the liver [4]. In
addition, systemic IR is characterised by ectopic triacylglyc-
erol accumulation in skeletal muscle and the liver [5]. Other
pathways implicated in systemic IR include low-grade inflam-
mation in white adipose tissue (WAT) [6].
An unfavourable intrauterine environment is associated
with IR in adulthood suggesting a, possibly epigenetically
regulated, metabolic memory [7]. The term ‘epigenetics’ re-
fers to stable long-term alterations in the transcriptional poten-
tial of cells and includes histone modifications and DNA
methylation, the latter occurring mainly in the context of CG
dinucleotides (CpGs) [8]. In any given individual, the epige-
netic profiles can differ substantially between different organs
and cell types [9]. In WAT, global as well as site-specific
differences in CpG methylation have been associated with
obesity and type 2 diabetes [10–12]. A recent epigenome-
wide association study identified one locus where CpG meth-
ylation in CD4+ Tcells is significantly associatedwith IR [13].
However, to our knowledge, no study of genome-wide CpG
methylation profiling in the organs directly implicated in the
development of IR has previously been reported.
The aim of this study was to explore whether systemic IR is
associated with epigenetic dysregulation of WAT, determined
by genome-wide CpG methylation and gene expression pro-
filing in subcutaneous adipose tissue (SAT) and VAT. Adipose
tissue is not ideal for routine clinical examinations; therefore,
a secondary aim was to determine whether the DNA methyl-
ation signature in peripheral blood mononuclear cells
(PBMCs) reflects WAT methylation and may thus be used as
a marker for systemic IR.
Methods
Participants and clinical evaluation The 80 women included
in this study were selected from the extremes of insulin sensi-
tivity, as measured by HOMA-IR [14], from 220 obese women
who participated in a clinical trial on the effect of bariatric
surgery (ClinicalTrial.gov registration no. NCT01785134).
The sample size was selected based on previous experience
from transcriptome and DNA methylation profiling on WAT
in relation to clinical metabolic phenotypes [10]. Of the 80
women, none had undergone any active weight-reducing at-
tempt for at least 6 months prior to surgery. Eight women were
diagnosed with hypertension, seven of which were prescribed
antihypertensive treatment (ACE inhibitors, n=3; diuretics,
n= 2; calcium-channel blockers, n= 2; β-blockers, n= 5).
Eleven patients were prescribed antidepressants, and one pa-
tient was taking methylphenidate for attention deficit hyperac-
tivity disorder. Mild impaired kidney function (n=1), obstruc-
tive sleep apnoea (n=1), von Willebrand’s disease (n=1) and
substituted vitamin B12 deficiency (n=1) were each diag-
nosed. Otherwise, participants were healthy according to med-
ical history. All sampling and measurements were performed
before or during bariatric surgery (laparoscopic gastric bypass).
Participants were investigated at 08:00 hours after an over-
night fast. Anthropometric measurements were performed
followed by venous blood sampling. Blood glucose and lipids
were analysed at the Karolinska University hospital’s routine
chemistry laboratory (Stockholm, Sweden). Plasma insulin
was measured by ELISA (Mercodia, Uppsala, Sweden) as
previously described [15]. Insulin sensitivity was assessed
by HOMA-IR and was calculated from fasting measures of
glucose and insulin as described [14]. High HOMA-IR values
indicate IR. The 40women with the highest HOMA-IR values
and the 40 women with the lowest values were selected for
inclusion in the present study. PBMCs were isolated in BD
Vacutainer Cell Preparation tubes (Becton, Dickinson San
Jose, CA, USA) and stored as pellets at −80°C for further
analysis.
The study was approved by the Regional Ethics Committee
in Stockholm and all participants gave their written informed
consent prior to participation. The study was carried out in
accordance with the principles of the Declaration of Helsinki
as revised in 2008.
WATsampling Biopsies from the abdominal SAT depot were
obtained from the surgical incision. Omental adipose tissue
(visceral adipose tissue [VAT]) specimens were obtained using
ultrasound scissors immediately after surgeons entered the
abdominal cavity. Participants were fasted overnight and
154 mmol/l NaCl was given by i.v. infusion until adipose
tissue specimens were removed. All WAT samples were rap-
idly rinsed in NaCl (154 mmol/l) and specimens of 300 mg
unfractionated WAT were immediately frozen in liquid
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nitrogen and kept at −70°C for subsequent DNA and RNA
preparation.
Global transcriptome assays From high-quality total RNAwe
prepared and hybridised biotinylated complementary RNA to
GeneChip Human Transcriptome Arrays 2.0 (HTA;
Affymetrix, Santa Clara, CA, USA) as described in the electron-
ic supplementary material (ESM) Methods. Of the 23,442
probesets annotated with a gene symbol, 5860 (25%) transcripts
with the lowestmean expression and 5860 (25%)with the lowest
variation in expression (i.e. SD divided by mean expression)
were excluded, resulting in 11,722 probesets being taken for-
ward for subsequent analysis of differentially expressed genes.
The applied cut-off for mean expression was used to exclude a
set of organ-specific genes that should not be expressed in adi-
pose tissue according to the literature. Webgestalt (http://bioinfo.
vanderbilt.edu/webgestalt/) was used to identify pathways over-
represented among differentially expressed genes and differen-
tially methylated sites (DMS) [16].
DNA methylation microarray assays DNA extracted from
SATandVATpieces, aswell as fromPBMCs,was assayed using
the Infinium Human Methylation 450 (450 K) BeadChips
(Illumina, San Diego, CA, USA) as described in ESM
Methods [17]. BeadChip images were processed as described
in ESMMethods. For differential methylation analysis,β values
were converted toM values (M=Log2[β/(1−β)]), which have a
more appropriate distribution for statistical tests for comparisons
between groups. Before analysis of DMS a number of filtering
steps were performed resulting in 112,057 (SAT), 124,089
(VAT) and 99,462 (PBMCs) probes, respectively, being taken
forward to identify DMS.
Methylation data have been deposited in the National
Center for Biotechnology Information Gene Expression
Omnibus (GEO; http://ncbi.nlm.nih.gov/geo, accession
number GSE76399).
Validation experiments Ten differentially expressed genes
with DMS in SAT were selected for validation experiments.
The genes were selected because they displayed consistent re-
sults in SAT and either VAT or PBMCs, or because they were
mentioned in the Discussion. Gene expression was measured
by quantitative real time-PCR (qPCR) using recommended
inventoried Taqman assays from Applied Biosystems
(Thermo Fisher Scientific, Waltham, MA, USA). Each sample
was analysed once. Group assignment was blinded during
experimentation.
Eleven DMS in SAT, in seven genes, were selected for
validation by EpiTYPER (Agena Biosciences, San Diego,
CA, USA), see ESM Methods for details. We were unable to
design EpiTYPER assays for DMS in some differentially
expressed genes validated by qPCR. We therefore selected a
DMS COL4A1 for confirmation although this gene was not
quantified by qPCR.
Statistical analysisWeused the Bioconductor package, Limma
(https://bioconductor.org/packages/release/bioc/html/limma.
html) to analyse the methylation M values to identify DMS
between insulin-resistant and insulin-sensitive women, adjusting
for BMI and age [18–20]. A threshold of p<0.05was used in the
epigenetic analysis. We also used parametric analysis in Limma
to compare gene expression levels (Log2) between the insulin-
resistant and insulin-sensitive groups adjusting for BMI. In tran-
scriptome analysis a thresholds false discovery rate (FDR) of
10% was used. A t test was applied to compare clinical pheno-
types, average global DNA methylation and validation results
(qPCR and EpiTYPER) between the insulin-resistant and
insulin-sensitive groups; a χ2 test was used to compare
proportions.
Results
Clinical characteristics of participants The clinical charac-
teristics of the included participants are detailed in Table 1. As
expected from the study design, the insulin-resistant group
had substantially higher HOMA-IR, fasting plasma glucose
and fasting serum insulin as compared with the insulin-
sensitive group. The insulin-resistant group also displayed
higher body weight, BMI, waist circumference and plasma
triacylglycerol concentrations. Total and HDL-cholesterol
levels were similar and there was no significant difference in
age when comparing the groups. Thus, the groups were rep-
resentative of the insulin-resistant or insulin-sensitive state.








Age (years) 36.4 ± 6.3 35.7 ± 5.7 0.57
Weight (kg) 116.8 ± 16.7 110.1 ± 11.7 0.04
BMI (kg/m2) 42.7 ± 4.7 39.1 ± 3.0 8.37× 10−5
Waist circumference (cm) 129.8 ± 11.9 122.3 ± 11.1 0.0061
fP Glucose (mmol/l) 6.0 ± 1.3 5.1 ± 0.4 9.07× 10−5
fS Insulin (pmol/l) 127 ± 39 29 ± 8 1.29× 10−25
HOMA-IR 5.6 ± 2.0 1.1 ± 0.3 7.11 × 10−23
fS Cholesterol (mmol/l) 4.6 ± 1.1 4.5 ± 0.9 0.64
fS HDL-cholesterol
(mmol/l)
1.1 ± 0.4 1.2 ± 0.3 0.78
fS Triacylglycerols
(mmol/l)
1.45 ± 0.7 1.02 ± 0.4 0.000786
Data are means ± SD; all participants are women
Groups were compared with t test
fP, fasting plasma; fS, fasting serum
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Transcriptome profile in SAT and VAT Comparison of the
expression levels of 11,722 transcripts between insulin-
resistant and insulin-sensitive women adjusted for BMI iden-
tified 647 differentially expressed genes in SAT (represented
by 656 probesets, FDR 10% [see ESM Table 1]). Expression
of ten differentially expressed genes in SATwas confirmed by
qPCR; all displayed directionally consistent results between
insulin-resistant and insulin-sensitive women in both microar-
ray and qPCR analysis, of which eight genes remained nom-
inally significant with qPCR (ESM Table 2). We compared
these results with previously reported genome-wide tran-
scriptome analyses of SAT between insulin-resistant and
insulin-sensitive individuals according to HOMA-IR.
Among 321 differentially expressed genes in SAT of 40
European-Americans, reported by Elbein et al (FDR 5%)
[21], 26 genes overlapped with the present study, all of which
displayed directionally consistent change in expression
(p<3.4×10−7). Among 373 differentially expressed genes in
SAT (top/bottom 20%) from 323 individuals, reported by
Qatanani et al [22], 19 genes overlapped with the present
study and 18 of these displayed directional consistency
(p<9.6×10−5) (ESM Table 1).
The 647 differentially expressed genes were over-represented
for a number of pathways (Table 2), including pathways related
to inflammation and immunity (e.g. TNF-related apoptosis-in-
ducing ligand [TRAIL] signalling, IL3-mediated signalling and
vascular endothelial growth factor receptor [VEGFR] signal-
ling), which is in agreement with the findings by Elbein et al
[21] and Qatanani et al [22]. As expected, genes in the insulin
signalling pathway were also over-represented. The 70 differen-
tially expressed genes in the insulin signalling pathway are
shown in ESM Table 3 and include IRS2, which was downreg-
ulated by 15%, and IL6R, which was upregulated by 7% in
insulin-resistant women.
In VAT there were 51 differentially expressed genes (rep-
resented by 52 probesets) between insulin-resistant and
insulin-sensitive women at FDR 10% (Table 3). For compar-
ison, Qatanani et al [22] reported 788 differentially expressed
genes in VAT between insulin-resistant and insulin-sensitive
individuals (top/bottom 20%), out of which eight genes over-
lapped with the 51 differentially expressed genes in the pres-
ent study (i.e. GSDMB [fold changes insulin-resistant vs insu-
lin-sensitive: 0.82], AGPAT9 [0.78], PAIP2B [0.85], CA3
[0.45], SERPINI1 [0.91], RASSF4 [1.13], MYD88 [1.09],
SLCO2B1 [1.24]); all eight genes displayed directionally con-
sistent expression in both studies (p < 4.7 × 10−3) [22]
(Table 3). The 51 differentially expressed genes in VAT in
our study were not over-represented for any specific pathway.
To assess possible depot-specific differences in gene expres-
sion, we overlapped the gene array data from VAT and SAT.
ESM Fig. 1 a shows a histogram of the per-gene correlation
between gene expression in VAT and SAT tissue samples and
Fig. 1b shows a boxplot of between-sample correlation. As
expected, within-participant correlation is higher than be-
tween-participant. All 51 differentially expressed genes in
VAT displayed directionally consistent differences in expres-
sion in SAT between insulin-resistant and insulin-sensitive
women, and 30 of these genes were significant (FDR 10%;
Table 3). Conversely, of the 647 differentially expressed genes
in SAT, all displayed directionally consistent differences in
VAT (ESM Table 1), 209 of which were nominally significant
(p≤0.05). The magnitude of the difference in expression of
these genes between insulin-resistant and insulin-sensitive
women was comparable between VAT (median difference in
expression 8.8%; range 3.8–23.9%) and SAT (median 10.7%;
range 4.6–38.5%). For individual genes, the median difference
in ratio of expression between insulin-resistant and insulin-
sensitive women was 0.027% (range 0.005–23.0%) between
adipose depots. Together, these comparisons suggest that in
the present cohort, IR is associated with similar dysregulations
of gene expression in the examined WAT depots.
Global pattern of CpG methylation The average degree of
DNA methylation (i.e. the average β value for all probes
Table 2 Over-representation of specific gene-sets among differentially
expressed genes in SAT between insulin-resistant and insulin-sensitive
womena
Pathwayc Observedb Expectedb Adjusted
p value
TRAIL signalling pathway 73 49 0.0024










S1P1 pathway 70 47 0.0024
IFN-γ pathway 70 48 0.0024
ErbB1 downstream signalling 70 47 0.0024








IGF1 pathway 70 47 0.0024
Insulin pathway 70 47 0.0024
Arf6 signalling events 70 47 0.0024
aWebgestalt was used to identify over-represented gene-sets (Pathway
commons) among 647 differentially expressed genes as compared with
all 11,722 analysed genes using default settings
b Number of differentially expressed genes
Arf6, ADP-ribosylation factor 6; ErbB1, epidermal growth factor recep-
tor; GMCSF, granulocyte-macrophage colony-stimulating factor; PAR1,
proteinase-activated receptor 1; S1P1, sphingosine-1-phosphate receptor;
uPAR, plasminogen activated receptor urokinase type
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Table 3 Differentially expressed genes in VAT between insulin-resistant and insulin-sensitive women
Probeset Gene VAT VATa SAT
IR IS IR/IS Adjusted p valueb IR/IS IS IR/IS Adjusted p valueb
TC09001184.hg.1 PGM5-AS1 174 (27) 219 (34) 0.79 0.002 127 0.87
TC09001281.hg.1 GKAP1 56 (4) 63 (6) 0.89 0.002 56 0.90 0.021
TC17002851.hg.1 GSDMB 92 (10) 112 (19) 0.82 0.0082 0.84 91 0.84 0.016
TC04000460.hg.1 AGPAT9 70 (12) 89 (18) 0.78 0.022 0.79 55 1.00
TC12000227.hg.1 PDE3A 109 (22) 133 (22) 0.82 0.028 100 0.82 0.033
TC09001585.hg.1 SCAI 62 (5) 69 (7) 0.90 0.034 67 0.88 0.016
TC15000030.hg.1 GOLGA8IP 195 (17) 217 (22) 0.90 0.034 186 0.93 0.08
TC05000782.hg.1 ARHGAP26 127 (18) 109 (13) 1.16 0.034 111 1.09 0.078
TC22000816.hg.1 ST13 499 (38) 558 (57) 0.89 0.035 537 0.89 0.016
TC20000575.hg.1 SIGLEC1 189 (30) 164 (18) 1.15 0.035 164 1.11 0.072
TC09000495.hg.1 ANP32B 215 (14) 237 (21) 0.91 0.038 244 0.92 0.019
TC15000157.hg.1 GOLGA8J 228 (24) 257 (28) 0.89 0.038 203 0.91 0.03
TC05000212.hg.1 ISL1 80 (10) 99 (25) 0.80 0.041 29 0.99
TC02001974.hg.1 PAIP2B 96 (10) 114 (17) 0.85 0.042 0.93 87 0.89
TC15002013.hg.1 TARSL2 79 (4) 86 (7) 0.92 0.043 83 0.94 0.078
TC05001954.hg.1 FAT2 56 (7) 49 (5) 1.14 0.043 76 1.11
TC01003789.hg.1 ST13P19 52 (5) 58 (6) 0.89 0.043 51 0.91 0.048
TC15002805.hg.1 ULK4P1 172 (38) 220 (50) 0.78 0.047 142 0.82 0.019
TC17001703.hg.1 MBTD1 106 (7) 116 (11) 0.91 0.048 109 0.92 0.031
TC20000926.hg.1 KCNB1 150 (20) 127 (23) 1.18 0.052 159 1.12
TC06004132.hg.1 MOCS1 162 (33) 205 (40) 0.79 0.052 190 0.86 0.014
TC05001714.hg.1 LOX 206 (38) 169 (29) 1.22 0.052 291 1.07
TC05001317.hg.1 CCL28 58 (4) 63 (6) 0.91 0.058 61 0.97
TC07001811.hg.1 AASS 103 (11) 118 (16) 0.88 0.059 95 0.85 0.021
TC08002581.hg.1 CA3 110 (59) 242 (176) 0.45 0.062 0.42 99 0.81
TC03000892.hg.1 SERPINI1 49 (5) 54 (6) 0.91 0.062 0.81 36 0.95
TC11000898.hg.1 NAALAD2 39 (7) 48 (10) 0.80 0.066 54 0.74 0.019
TC15000160.hg.1 ULK4P3 147 (37) 188 (43) 0.78 0.07 115 0.80 0.02
TC01000619.hg.1 CDKN2C 110 (18) 134 (25) 0.82 0.072 134 0.92
TC10000289.hg.1 RASSF4 142 (19) 126 (13) 1.13 0.072 1.23 153 1.12 0.059
TC19000034.hg.1 CIRBP 565 (44) 615 (54) 0.92 0.072 564 0.97
TC18000224.hg.1 PHLPP1 91 (6) 101 (9) 0.91 0.072 105 0.89 0.03
TC13000436.hg.1 UPF3A 177 (13) 190 (16) 0.93 0.072 209 0.96
TC04001410.hg.1 ADH1B 3013 (467) 3478 (495) 0.87 0.074 3236 0.80 0.017
TC15001546.hg.1 DAPK2 146 (21) 171 (26) 0.86 0.074 159 0.85 0.0088
TC04001305.hg.1 CXCL10 60 (57) 36 (11) 1.67 0.074 57 0.99
TC09000319.hg.1 TJP2 166 (14) 179 (14) 0.93 0.074 194 0.98
TC03000187.hg.1 MYD88 172 (16) 158 (14) 1.09 0.076 1.12 193 1.06
TC07001493.hg.1 GTF2IRD2P1 151 (14) 163 (15) 0.92 0.081 158 0.92
TC02002891.hg.1 ARL4C 77 (9) 69 (10) 1.12 0.081 61 1.09
TC09002904.hg.1 NIPSNAP3B 78 (20) 102 (28) 0.77 0.081 96 0.77 0.019
TC12001300.hg.1 ABCC9 338 (63) 391 (63) 0.86 0.082 630 0.75 0.0026
TC12001299.hg.1 KCNJ8 129 (11) 142 (14) 0.91 0.088 144 0.89 0.02
TC11000933.hg.1 CEP57 98 (7) 107 (13) 0.92 0.089 110 0.89 0.019
TC11000802.hg.1 SLCO2B1 264 (66) 213 (52) 1.24 0.094 1.26 217 1.19 0.087
TC02000395.hg.1 PNO1 57 (5) 53 (4) 1.08 0.094 71 1.06
TC01001043.hg.1 PHGDH 119 (15) 135 (22) 0.88 0.094 92 0.91
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remaining after filtering) was compared between the insulin-
resistant and insulin-sensitive groups. There were no signifi-
cant differences in either SAT (insulin-resistant 0.504±0.019
[average β value ± SD]); insulin-sensitive 0.507 ± 0.013),
VAT (insulin-resistant 0.483±0.014; insulin-sensitive 0.477
±0.022) or PBMCs (insulin-resistant 0.508±0.020; insulin-
sensitive 0.510±0.015). The average level of DNA methyla-
tion stratified by genome region in relation to CpG content
and functional parts of genes is shown in Fig. 1.
DMS in SAT Comparison of CpG methylation in SAT be-
tween insulin-resistant and insulin-sensitive women was
assessed at 112,057 sites. Although none of the DMS were
significant after FDR correction, 10,746 were nominally sig-
nificant with median differences in methylation of 0.024
(range 4×10−4 to 0.092) between groups (p≤0.05). These
data were compared with results from other DNAmethylation
profiling studies on SAT applying the same 450 K platform.
Nilsson et al reported, in a cohort of 56 individuals, 15,627
DMS (q<0.15) in WAT associated with type 2 diabetes [10];
671 of the DMS overlapped with those in the present study, of
which 592 displayed directionally consistent differences in
methylation in both cohorts (p<2.7×10−87) (ESM Table 4)
[10]. In a study of 190 men and women, Rönn et al identified
Table 3 (continued)
Probeset Gene VAT VATa SAT
IR IS IR/IS Adjusted p valueb IR/IS IS IR/IS Adjusted p valueb
TC11001197.hg.1 ADAMTS15 98 (12) 88 (10) 1.11 0.094 110 1.28 0.021
TC18000132.hg.1 RNF125 95 (10) 109 (15) 0.88 0.094 104 0.95
TC02002086.hg.1 ANKRD20A8P 42 (6) 47 (7) 0.91 0.094 41 0.92 0.07
TC01001866.hg.1 ADCK3 181 (13) 201 (23) 0.90 0.095 192 0.93 0.071
Data are shown as average (SD) for VAT or average for SAT
aComparison with published transcriptome profile [27] on VAT from insulin-resistant vs insulin-sensitive individuals
b Gene expression was compared between groups using Limma and adjusting for BMI; threshold FDR< 10%



























































































Fig. 1 DNA methylation
landscape in insulin-resistant vs
insulin-sensitive women in SAT
(a, d), VAT (b, e) and PBMCs (c,
f). Based on Illumina annotation,
112,057 (SAT), 124,089 (VAT)
and 99,462 (PBMCs) CpG probes
were mapped to genome regions.
We calculated the average level of
DNA methylation within each of
the insulin-resistant (black bars)
and insulin-sensitive (white bars)
groups stratified on genome
region in relation to functional
gene regions (a, b, d) and CpG
content (d, e, f). TSS1500, within
1500 bp of transcriptional start
site (TSS); TSS200, within
200 bp of TSS. Genome
locations: Island, CpG island; N_
Shelf, upstream CpG island shelf;
N_Shore, upstream CpG island
shore; S_Shore, downstreamCpG
island shore; S_Shelf,
downstream CpG island shelf;
Open_sea; other CpG regions
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39,533 CpG sites whose methylation in WAT of women was
associated with BMI. Of these BMI-associated CpG sites,
2052 overlapped with the present study and 1973 displayed
directionally consistent differences in methylation
(p< 1× 10−90) (ESM Table 4) [20]. Benton et al reported
3601 DMS before vs after weight loss induced by bariatric
surgery [12]. Ninety-three DMS overlapped with the present
study out of which 91 sites displayed directionally consistent
results between obese individuals before weight loss and
insulin-resistant individuals (p<2.7×10−20) (ESM Table 4).
Eleven DMS were confirmed by EpiTYPER; nine displayed
directionally consistent results between insulin-resistant and
insulin-sensitive women in both microarray and EpiTYPER
analysis, of which four remained nominally significant, and
three more were close to significance (p < 0.06) (ESM
Table 2). It is worth noting that, of the DMS analysed by
EpiTYPER, seven had been previously reported, all of which
were confirmed by the present study.
Next, we merged the 647 differentially expressed genes in
SAT with the 10,746 DMS and identified 223 IR-associated
genes containing a total of 336 DMS (ESM Table 5). These
genes are evenly distributed in the genome, and each gene
contains one or a few DMS (Fig. 2). A subset of these genes
is listed in Table 4. Twenty-nine genes displayed direct, pos-
itive or negative, correlation between gene expression and
methylation (ESM Table 6). Whereas CpG methylation in 5’
regions of genes has classically been associated with reduced
gene expression, CpG methylation in gene bodies has been
reported to stimulate gene expression [23]. It was therefore of
interest to map the IR-associated DMS in relation to gene
region, and relate the degree of methylation to gene expres-
sion. Among 158 DMS in 5’ regions of genes, 67 CpG sites
displayed reciprocal direction of effect between gene expres-
sion and CpG methylation. Among 178 DMS in gene bodies
and 3’ untranslated regions (3’UTRs), 80 CpG sites displayed
a positive association between changes in DNA methylation
and gene expression. Thus, there was no evidence that DNA
methylation in the 5’ regions of genes preferentially repressed
gene expression, nor the opposite in gene bodies.
The 223 IR-associated genes were over-represented for
pathways related to integrin cell surface interactions, focal
adhesion and insulin signalling (ESM Table 7). Data for the
insulin signalling genes are shown in Table 5.
DMS in VAT CpG methylation in VAT was assessed at
124,089 sites. Although none of the DMS were significant
after FDR correction, 10,217 were nominally significant
(p ≤ 0.05) between insulin-resistant and insulin-sensitive
women with median difference in methylation of 0.028 (range
0.001–0.105) (ESM Table 8). We mapped the 10,217 DMS
from the present study to other DNA methylation profiling
studies in VAT that used the 450 K platform. Benton et al
reported 15 DMS in VAT before vs after weight loss induced
by bariatric surgery, of which two CpG sites displayed nom-
inally significant and directionally consistent results in the
present study (p<0.2) (ESM Table 8) [12]. Guenard et al
listed 83 DMS in VAT associated with the metabolic syn-
drome [24] and, of these, none were differentially methylated
in VAT between insulin-resistant and insulin-sensitive women
in the present study. Finally, we compared results between
SAT and VAT in the present study. Among nominally signif-
icant DMS between insulin-resistant and insulin-sensitive
women, 1455 CpG sites overlapped between SAT and VAT,
1406 of which displayed directionally consistent results be-
tween depots (ESM Table 8).
Next, we merged the 51 differentially associated expressed
genes in VATwith the 10,217 DMS and thus identified 18 IR-
associated genes containing a total of 29 DMS (Table 6).
There were three DMS in two differentially expressed genes
that were common between SAT and VAT; cg14229247 (in
ANP32B), and cg08400424 and cg11796181 (both in
ARHGAP26) (Table 6). cg14229247 in ANP32B could not
be confirmed by EpiTYPER, whereas we were unable to de-
sign assays for the DMS in ARHGAP26, leaving some uncer-
tainty to these results (ESM Table 2). Four genes displayed
direct, positive or negative, correlation between gene expres-
sion and methylation in VAT (ESM Table 6). Of the 11 DMS
in the 5′ region of genes, seven CpG sites displayed an inverse
association between gene expression andmethylation. Among
18 DMS in gene bodies and 3′UTR regions, two CpG sites
displayed coherent changes.
DMS in PBMCs We investigated whether IR was associated
with systemic epigenetic differences by analysing DNAmethyl-
ation profiles in PBMCs. There were no significant DMS after
correction for multiple testing among the 99,462 analysed CpG
sites, although 2451 were nominally significant with median
differences in methylation of 0.021 (range 7×10−5–0.130) be-
tween groups (p≤0.05) (ESM Table 9). There were 268 DMS
that overlapped between SAT and PBMCs, of which 109
displayed directionally consistent results (ESM Table 4).
Among DMS accompanied by differential gene expression in
SAT, only three CpG sites displayed significant differentialmeth-
ylation in a consistent direction in PBMCs: ADAMTS2
cg26694831, average difference in β value between the
insulin-resistant and insulin-sensitive women in SAT −0.037
and PBMCs −0.044 (p = 0.005), respectively; FIP1L1
cg19408398, average difference in SAT 0.026 and PBMCs
0.034 (p=0.012), respectively; SAMD4A cg06633081 average
difference in SAT −0.033 and PBMCs −0.027 (p=0.048), re-
spectively. EpiTYPER analyses of these CpG sites in SATwere
non-significant, although DMS in ADAMTS2 and FIP1L1
remained directionally consistent (ESM Table 2).
Cell-mixture-adjusted analysis of DMS We applied a
reference-free algorithm for cell-mixture adjustment to detect
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DMS, and compared the results with our original whole-tissue-
based results [25]. There were 2669, 14,410, and 949 DMS in
SAT, VAT and PBMCs, respectively, after cell-mixture adjust-
ment. The number of DMS overlapping between the cell-
mixture-adjusted analysis and our original analysis was 948
for SAT, 2059 for VAT and 380 for PBMCs; of these 943,
1999 and 379 DMS, respectively, displayed directionally con-
sistent results (ESM Tables 10–12).
Discussion
Previous studies have linked WAT CpG methylation to adi-
posity and type 2 diabetes. Here, for the first time we report a
comprehensive analysis of IR-associated DMS and their cor-
relation with gene expression in SAT and VAT.
VAT mass is more strongly associated with IR than SAT, as
reviewed [26]. In our genome-wide transcriptome analysis,
however, there were a greater number of genes that were dif-
ferentially expressed in SAT than in VAT in the insulin-resistant
state. Nevertheless, the majority of the IR-associated genes
displayed differences in expression that were directionally con-
sistent between SATand VAT. Together, these data suggest that
there is no depot-specific transcriptomic signature that is asso-
ciated with systemic IR. In agreement with this, Klimcáková
et al reported similar alterations in the two adipose depots of
obese patients with unfavourable metabolic status [27]. This
suggests that other factors, such as the amount of VAT or the
metabolite profile, could be more important for determining the
effect of VAT on IR or other metabolic disorders. We confirm
that IR-associated genes in WAT are over-represented for path-
ways related to immune response and angiogenesis (VEGFR
signalling in the present study), whereas reported over-
representation of genes important for cell cycle regulation and
metabolism was not observed [21, 22]. The reason for the latter
discrepancy could be due to selection of study participants.
There were no global differences in DNA methylation
between the insulin-resistant and insulin-sensitive women
in any of the studied tissues. A number of genes in both
SAT and VAT displayed differential methylation accompa-
nied by differential gene expression in insulin-resistant as
compared with insulin-sensitive women. We did not observe
any significant DMS between the insulin-resistant and
insulin-sensitive groups after adjustment for multiple testing
in the present dataset. However, considering all nominally
significant DMS in the present study (which admittedly in-
clude false-positives), the vast majority of DMS that overlap
between the present study and previous studies of BMI or
type 2 diabetes display directionally consistent methylation
differences in the reported cohorts. Furthermore, of the DMS
analysed by EpiTYPER, seven had been previously reported
and they were all confirmed. This observation suggests that
many DMS are real, despite not reaching formal statistical
significance in the present study. Traditionally, methylation
of CpG islands in promoters has been associated with re-
pression of gene expression whereas CpG sites in gene
Fig. 2 Chromosomal position of
223 IR-associated genes
containing a total of 336 DMS.
Inner circle shows gene
expression data (blue,
upregulated expression in IR;
yellow, downregulated
expression in IR), outer circle
represents methylation data (blue,
high methylation in IR; yellow,
low methylation in IR)
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Table 4 A subset of differentially expressed genes accompanied by DMS in SAT between insulin-resistant vs insulin-sensitive womena
Probe Gene Relation to
gene region
DNA methylation Gene expression
IS average IR − IS p value T2Db,c [10] BMIb,d [20] GBPb,e [12] IS average IR/IS p value
cg07251857 ALPK3 1st exon 0.546 0.026 0.022 0.016 76 0.89 2.56× 10−3
cg06532379 ALPK3 1st exon 0.193 0.039 0.015 0.015 76 0.89 2.56× 10−3
cg14080050 B4GALT1 Body 0.447 −0.037 0.015 −0.014 228 1.10 1.48× 10−3
cg13858803 B4GALT1 Body 0.566 0.027 0.040 0.027 228 1.10 1.48× 10−3
cg00300298 BCL2L1 Body 0.251 −0.037 0.038 −0.019 151 1.07 2.01× 10−3
cg12873919 BCL2L1 Body 0.504 −0.036 0.032 151 1.07 2.01× 10−3
cg03290977 C1QTNF7 Body 0.247 −0.035 0.034 −0.024 44 0.86 3.28x10−3
cg01939704 C1QTNF7 Body 0.616 0.020 0.022 44 0.86 3.28× 10−3
cg07538039 C1QTNF7 Body 0.610 0.025 0.021 44 0.86 3.28× 10−3
cg06097727 C1QTNF7 Body 0.547 0.035 0.043 0.016 44 0.86 3.28× 10−3
cg24829483 C1QTNF7 5′UTR 0.633 0.039 0.034 44 0.86 3.28× 10−3
cg00545229 C1QTNF7 TSS200 0.563 0.041 0.018 44 0.86 3.28× 10−3
cg15372098 C3orf26 Body 0.027 −0.016 0.014 69 0.92 3.98× 10−4
cg00991994 C3orf26 Body 0.401 0.055 0.039 0.067 0.035 69 0.92 3.98× 10−4
cg17351376 CD248 1st exon 0.504 0.019 0.032 239 1.42 1.03× 10−3
cg07145284 CD248 TSS200 0.085 0.029 0.038 0.018 239 1.42 1.03× 10−3
cg00350296 CD248 TSS1500 0.158 0.041 0.018 0.022 239 1.42 1.03× 10−3
cg13860849 CD248 1st exon 0.191 0.054 0.002 0.015 239 1.42 1.03× 10−3
cg10772263 CHST3 5′UTR 0.322 0.020 0.028 0.025 113 1.17 1.31× 10−3
cg04268405 CHST3 TSS1500 0.369 0.042 0.024 0.219 113 1.17 1.31× 10−3
cg12081643 COL4A1 3′UTR 0.670 −0.042 0.008 530 1.17 1.34× 10−3
cg20818806 COL4A1 Body 0.299 0.042 0.019 530 1.17 1.34× 10−3
cg02658690 COL4A1 Body 0.207 0.042 0.014 0.218 530 1.17 1.34× 10−3
cg10908116 COL4A1 Body 0.247 0.043 0.017 0.053 0.026 530 1.17 1.34× 10−3
cg02099572 COL4A1 Body 0.140 0.047 0.005 0.056 530 1.17 1.34× 10−3
cg03430597 COL5A1 Body 0.751 0.018 0.004 0.018 162 1.10 5.97× 10−4
cg24354213 COL5A1 Body 0.601 0.027 0.023 0.014 162 1.10 5.97× 10−4
cg14274542 COL5A1 Body 0.596 0.037 0.019 0.012 162 1.10 5.97× 10−4
cg10765212 COL5A2 TSS200 0.129 0.021 0.047 246 1.20 3.25× 10−4
cg15194531 FMNL1 Body 0.466 0.041 0.005 0.018 165 1.09 5.32× 10−4
cg08145262 FRS2 5′UTR 0.658 0.031 0.020 0.020 155 0.93 1.64× 10−3
cg19563525 FRS2 5′UTR 0.382 0.035 0.006 0.017 155 0.93 1.64× 10−3
cg10227830 GAB1 Body 0.272 0.039 0.016 141 0.89 1.53× 10−4
cg25911551 GAB1 Body 0.494 0.046 0.049 0.019 141 0.89 1.53× 10−4
cg08202226 GATAD2B TSS1500 0.793 −0.057 0.018 −0.029 282 0.94 3.97× 10−3
cg05514401 IRS2 1st exon 0.792 0.031 0.002 0.028 242 0.85 1.24× 10−3
cg11624345 KCNN4 Body 0.391 0.025 0.025 0.014 87 1.06 4.11 × 10−3
cg03731131 KCNN4 Body 0.378 0.032 0.039 87 1.06 4.11 × 10−3
cg22904711 KCNN4 Body 0.313 0.060 0.002 0.047 0.015 87 1.06 4.11 × 10−3
cg14616541 MYH10 Body 0.834 0.024 0.010 292 0.87 1.64× 10−3
cg22588546 MYH10 Body 0.496 0.047 0.008 0.039 292 0.87 1.64× 10−3
cg21542094 PFKFB3 TSS1500 0.081 −0.001 0.025 −0.013 542 0.80 5.53× 10−5
cg00902516 PFKFB3 Body 0.739 0.020 0.019 0.016 542 0.80 5.53× 10−5
cg03261682 PFKFB3 Body 0.780 0.028 0.006 0.026 542 0.80 5.53× 10−5
cg05686026 PFKFB3 Body 0.683 0.045 0.001 0.033 542 0.80 5.53× 10−5
cg03478610 PPP2R3A 5′UTR 0.871 −0.031 0.034 −0.014 91 0.93 1.49× 10−3
cg00369142 PPP2R3A 3′UTR 0.378 0.044 0.013 0.060 0.025 91 0.93 1.49× 10−3
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bodies often display a positive association between methyl-
ation and expression [23]. In the present study there was no
evidence that DNA methylation in the 5′ regions of genes
preferentially repressed gene expression, nor the opposite in
gene bodies. Interestingly, the link between transcriptional
repression and DNA methylation is less clear for non-CpG
island promoters (CpG-poor promoters); many active genes
have methylated CpG-poor promoters [28]. Together, the
Table 5 Differentially expressed insulin signalling pathway genes accompanied by DMS in SAT between insulin-resistant and insulin-sensitive
womena
Probe Gene Relation to
gene region
DNA methylation Gene expression
IR IS IR− IS p value IS IR/IS p value
cg17133045 AKT3 Body 0.761 (0.047) 0.735 (0.051) 0.026 0.007 144 0.92 4.38× 10−3
cg04221461 AKT3 Body 0.524 (0.070) 0.490 (0.043) 0.034 0.002 144 0.92 4.38× 10−3
cg08428486 BRAF Body 0.807 (0.122) 0.833 (0.035) −0.026 0.048 235 0.92 3.96× 10−4
cg25204078 BRAF TSS1500 0.771 (0.040) 0.757 (0.042) 0.014 0.034 235 0.92 3.96× 10−4
cg06748146 HK1 Body 0.734 (0.047) 0.709 (0.044) 0.026 0.007 170 1.09 3.07× 10−3
cg05514401 IRS2 1st exon 0.823 (0.065) 0.792 (0.048) 0.031 0.002 242 0.85 1.24× 10−3
cg18932526 MAPK8 TSS1500 0.907 (0.099) 0.929 (0.020) −0.022 0.020 73 0.94 3.47× 10−3
cg19612574 MAPK8 TSS1500 0.935 (0.074) 0.950 (0.019) −0.015 0.022 73 0.94 3.47× 10−3
cg20994699 PDX103A Body 0.572 (0.092) 0.544 (0.086) 0.028 0.048 100 0.82 4.48× 10−4
cg03465562 PHKA2 Body 0.929 (0.092) 0.953 (0.019) −0.024 0.021 167 0.91 9.80× 10−4
DNA methylation data are expressed as average (SD); gene expression data are expressed as average
IR, insulin-resistant; IS, insulin-sensitive; TSS1500, within 1500 bp of transcriptional start site
Table 4 (continued)
Probe Gene Relation to
gene region
DNA methylation Gene expression
IS average IR − IS p value T2Db,c [10] BMIb,d [20] GBPb,e [12] IS average IR/IS p value
cg11468953 PTPRJ Body 0.519 −0.039 0.027 −0.020 139 1.18 3.07× 10−3
cg12124589 QSOX1 Body 0.775 −0.032 0.027 −0.020 175 1.08 1.70× 10−3
cg09505809 QSOX1 TSS1500 0.179 0.039 0.031 175 1.08 1.70× 10−3
cg00971364 RBMS3 TSS200 0.043 −0.018 0.034 381 0.90 5.14× 10−4
cg23537305 RBMS3 Body 0.819 0.016 0.045 0.017 381 0.90 5.14× 10−4
cg20299414 RBMS3 Body 0.729 0.035 0.018 0.013 381 0.90 5.14× 10−4
cg27569887 RBMS3 3′UTR 0.698 0.043 0.026 381 0.90 5.14× 10−4
cg16572224 SH3PXD2B Body 0.816 −0.049 0.002 −0.039 −0.019 145 1.13 4.76× 10−3
cg05223396 SH3PXD2B Body 0.404 0.025 0.049 145 1.13 4.76× 10−3
cg09744420 STX11 Body 0.654 0.041 0.002 0.020 356 0.89 2.98× 10−3
cg19841369 SYNE2 Body 0.159 0.028 0.044 0.016 236 0.89 2.18× 10−3
cg16725974 SYNE2 5′UTR 0.532 0.046 0.027 0.057 0.022 236 0.89 2.18× 10−3
cg23250157 SYNE2 Body 0.756 0.061 0.018 236 0.89 2.18× 10−3
cg18837713 ZDHHC17 Body 0.616 0.045 0.010 0.027 161 0.94 5.15× 10−3
a Differentially expressed genes (10% FDR) accompanied by DMS (p < 0.05) in SAT between insulin-resistant and insulin-sensitive women. Groups
were compared using Limma and adjusting for BMI (gene expression, DMS) and age (DMS). This table contains a subset of the ESM Table 4 and
focuses on DMS confirmed from the literature and mentioned in the discussion
b Comparison with published transcriptome profiles on SAT from insulin-resistant vs insulin-sensitive individuals
c T2D vs control
d Regression coefficient
e After vs before bariatric surgery and weight loss
IR, insulin-resistant; IS, insulin-sensitive; T2D, type 2 diabetes
2402 Diabetologia (2016) 59:2393–2405
above findings suggest that the relationship between CpG
methylation and IR is complex, comprising many CpG sites
that have a modest association with IR and a variable impact
on gene expression.
There were 223 IR-associated genes with DMS in SAT that
were over-represented for pathways related to integrin cell
surface interactions, focal adhesion and insulin signalling.
Integrins constitute a component of the extracellular matrix
and previously have been implicated in adipose remodelling
in conjunction with obesity and IR [29, 30]. Specific IR-
associated genes with DMS are listed in Table 7, together with
potential mechanisms that could explain their association with
insulin sensitivity (details on CpG methylation are given in
Table 4). These specific genes all have DMS that confirm
previous findings, and are associated with adipose tissue and
insulin signalling in the literature according to PubMatrix
(http://pubmatrix.grc.nia.nih.gov/, accessed 31 August 2015).
Although, overall, the CpG methylation in PBMCs did not
mirror DMS in SAT associated with IR, a few DMS accom-
panied by differential gene expression in SAT displayed sig-
nificant differential methylation in a direction consistent with
that in PBMCs. CpG methylation results for FIP1L1 and
ADAMTS2 remained directionally consistent in validation ex-
periments. FIP1L1 which encodes FIP 1-like, primarily
characterised as a fusion protein (FIP1L1-PDGFRA) in
hypereosinophilic disorders [34]. ADAMTS2 encodes
Table 6 Differentially expressed genes accompanied by DMS in VAT between insulin-resistant and insulin-sensitive womena
Probe Gene Relation to
gene region
DNA methylation Gene expression
IR IS IR− IS p value IS IR/IS p value
cg17174775 AASS TSS1500 0.016 0.039 0.027 0.033 −0.011 0.0022 118 0.88 0.000121
cg09711028 ABCC9 Body 0.913 0.041 0.897 0.046 0.016 0.033 391 0.86 0.000303
cg16236108 AGPAT9 TSS200 0.062 0.042 0.076 0.04 −0.014 0.027 89 0.78 7.62× 10−6
cg14229247b ANP32B TSS1500 0.04 0.048 0.048 0.046 −0.009 0.038 237 0.91 3.61× 10−5
cg08400424b ARHGAP26 Body 0.55 0.1 0.597 0.103 −0.047 0.028 109 1.16 2.33× 10−5
cg05185926 ARHGAP26 3′UTR 0.712 0.101 0.75 0.121 −0.038 0.025 109 1.16 2.33× 10−5
cg11796181b ARHGAP26 Body 0.754 0.043 0.708 0.047 0.046 0.00017 109 1.16 2.33× 10−5
cg12264626 CA3 TSS1500 0.183 0.054 0.162 0.095 0.021 0.036 242 0.45 0.000136
cg00908631 CDKN2C TSS1500 0.668 0.052 0.632 0.06 0.036 0.0011 134 0.82 0.000184
cg10156302 DAPK2 Body 0.605 0.091 0.552 0.111 0.053 0.01 171 0.86 0.000235
cg23165541 DAPK2 5′UTR 0.403 0.094 0.363 0.09 0.039 0.014 171 0.86 0.000235
cg06904649 DAPK2 Body 0.767 0.037 0.744 0.043 0.022 0.043 171 0.86 0.000235
cg16151151 ISL1 Body 0.196 0.069 0.172 0.095 0.024 0.016 99 0.8 0.000045
cg17686487 ISL1 Body 0.434 0.082 0.395 0.089 0.039 0.012 99 0.8 0.000045
cg16270526 ISL1 Body 0.225 0.069 0.185 0.077 0.04 0.023 99 0.8 0.000045
cg26422022 LOX TSS200 0.032 0.039 0.039 0.036 −0.007 0.040419 169 1.22 9.74× 10−5
cg22836153 LOX Body 0.057 0.038 0.065 0.033 −0.008 0.042 169 1.22 9.74× 10−5
cg03422350 MOCS1 Body 0.722 0.068 0.68 0.071 0.042 0.031 205 0.79 9.42× 10−5
cg10791278 MOCS1 Body 0.782 0.056 0.737 0.061 0.045 0.0016 205 0.79 9.42× 10−5
cg06023702 PAIP2B TSS200 0.029 0.043 0.04 0.041 −0.011 0.018 114 0.85 5.02× 10−5
cg06241044 PAIP2B 5′UTR 0.265 0.052 0.242 0.066 0.023 0.038 114 0.85 5.02× 10−5
cg22999327 PDE3A Body 0.53 0.105 0.485 0.124 0.045 0.028 133 0.82 1.19× 10−5
cg02631767 PDE3A Body 0.875 0.056 0.857 0.058 0.018 0.048 133 0.82 1.19× 10−5
cg04857033 PHGDH Body 0.376 0.078 0.336 0.089 0.04 0.049 135 0.88 0.00039
cg26166935 PHLPP1 Body 0.857 0.039 0.837 0.037 0.02 0.03 101 0.91 0.000203
cg03299121 PNO1 TSS200 0.055 0.044 0.064 0.041 −0.01 0.0003 53 1.08 0.000385
cg06123940 RNF125 TSS1500 0.798 0.044 0.785 0.043 0.012 0.029 109 0.88 0.0004
cg18101249 RNF125 Body 0.082 0.049 0.089 0.037 −0.006 0.046 109 0.88 0.0004
cg13849419 TJP2 Body 0.509 0.095 0.468 0.106 0.041 0.043 179 0.93 0.000239
DNA methylation data are expressed as average (SD); gene expression data are expressed as average
a Differentially expressed genes (10% FDR) accompanied by DMS (p < 0.05) in VAT between insulin-resistant and insulin-sensitive women. Groups
were compared using Limma and adjusting for BMI (gene expression, DMS) and age (DMS)
bDMS and differentially expressed gene common to SAT and VAT
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procollagen I N-proteinase that excises the N-propeptide of
type I and type II procollagens. Mutation in ADAMTS2
causes the connective tissue disease Ehlers–Danlos syn-
drome. None of these genes have been characterised in rela-
tion to insulin sensitivity. Neither PBMC, SAT nor VAT DNA
methylation signatures could confirm the previously reported
association of global leucocyte DNA methylation with IR
[35]. Furthermore, a DMS in the ABCG1 gene in T cells that
previously has been associated with HOMA-IR was not de-
tected in the present study [13]. In most cases differences in
both gene expression and DNA methylation between groups
in the present study were small. One reason for the small
differences in DNA methylation could be that DNA from
adipose tissue, which contains different cell types having po-
tentially different DNA methylation signatures, were studied.
Similarly we investigated unfractionated PBMCs, and the
DNA methylation pattern in subpopulations of these cells
may differ [9].
There are sex differences in insulin sensitivity [36] and
since we only investigated women it is unknown at present
whether DNA methylation may have a different role for IR in
obese men.
Conclusion
Whereas global DNA CpG methylation in adipose tissue
is not associated with systemic IR, specific genes display
differential expression in SAT accompanied by DMS. Such
genes include GAB1, IRS2, PFKFB3, and PTPRJ. Further
analysis of the function and epigenetic regulation of these
genes in fat cells will help determine their potential causal
role in systemic IR. CpG methylation in PBMCs does not
reflect DMS in WAT, suggesting that epigenetic analyses
in circulating leucocytes are not suitable for metabolic
phenotyping of obese individuals.
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Table 7 Selected IR-associated
genes with DMS Gene Expression and CpG-methylation in SAT:
observations from the current study
Previously reported findings of gene/protein
function
GAB1 SAT CpG methylation in the gene body was
inversely associated with gene expression
and IR was associated with lower GAB1
expression (fold change IR vs IS: 0.89)
GAB1 is an adaptor molecule that can stimulate
adipocyte glucose uptake through a GAB1/PI
3-kinase/PKB/AS160 pathway [31]
PFKFB3 SAT CpG methylation in the promoter was
directly associated with gene expression,
whilst CpG methylation in the gene body
was inversely associated. IR was associated
with lower PFKFB3 expression (fold change
IR vs IS: 0.80)
PFKFB3 regulates the steady-state
concentration of fructose-2,6-bisphosphate,
a potent activator of a key regulatory enzyme
of glycolysis. Fat cell overexpression of
PFKFB3 enhances insulin sensitivity [32]
IRS2 SAT CpG methylation in the 5′ region was
inversely associated with gene expression
and IR was associated with lower IRS2
expression (fold change IR vs IS: 0.85)
IRS2 mediates the effects of insulin on glucose
homeostasis and cell growth
PTPRJ SAT CpG methylation in the gene body was
inversely associated with gene expression
and IR was associated with higher PTPRJ
expression (fold change IR vs IS: 1.18)
Recently it was shown that high-fat diet fed
Ptprj−/− mice displayed enhanced insulin
sensitivity and improved glucose tolerance,
thus establishing PTPRJ as a negative
regulator of insulin signalling [33]
AS160, Akt substrate 160-KD; GAB1, growth factor receptor bound protein 2-associated binding protein 1;
PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3; PI 3-kinase, phosphatidylinositol 3-kinase;
PKB, protein kinase B; PTPRJ, protein-tyrosine phosphatases, receptor-type, J
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